$ABOS News

Last published 1w ago

1w agoABOSAcumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary EndpointGlobeNewswire-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months
2w agoABOSAcumen Pharma Q3 2026 Conference Call and Webcast - ACUMEN PHARMACEUTICALS INCEarnings Call TranscriptsGood day and welcome to the Acumen Pharmaceuticals third quarter 2026 conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and an
2w agoABOSAcumen Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
2w agoABOSAcumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewswireExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026IND filing for the Enhanced Brain Delivery™ (EBD®)
2w agoABOSAcumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceGlobeNewswireNEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers
3w agoABOSAcumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026GlobeNewswireNEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that
1mo agoABOSAcumen Pharma Investor Day - ACUMEN PHARMACEUTICALS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Investor Day conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a ques
2mo agoABOSAcumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026GlobeNewswireNEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that
2mo agoABOSAcumen Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireNEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers
3mo agoABOSAcumen Pharma Q2 2026 Conference Call and Webcast - ACUMEN PHARMACEUTICALS INCEarnings Call TranscriptsGood day, and welcome to the Acumen Pharmaceuticals second quarter 2026 conference call and webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and
3mo agoABOSAcumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business HighlightsGlobeNewswireExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Two candidates nominated for development in Acumen’s
3mo agoABOSAcumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026GlobeNewswireNEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that
3mo agoABOSAcumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026GlobeNewswireEBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the
4mo agoABOSAcumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026GlobeNewswireNEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers
4mo agoABOS TYO:4552JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology PlatformBusiness Wire- Strategic partnership, announced in July 2025, utilizes JCR's J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer's disease - Option exercise
4mo agoABOSAcumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's DiseaseGlobeNewswireACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR PharmaceuticalsEBD technology represents the only anti-amyloid oligomer program
6mo agoABOSAcumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswireExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's EBDTM
6mo agoABOSAcumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care ConferenceGlobeNewswireNEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for
6mo agoABOSAcumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026GlobeNewswireNEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble
7mo agoABOSAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business HighlightsGlobeNewswireExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's Enhanced
7mo agoABOSSTIFEL 2026 VIRTUAL CNS FORUM - ACUMEN PHARMACEUTICALS INCEarnings Call TranscriptsGreat. Thanks very much, everybody. It's my pleasure to be moderating this chat with the Acumen team. And maybe we'll have Dan O'Connell, founder, CEO, talk for a bit about just the background of the company and maybe se
8mo agoABOSAcumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery PortfolioGlobeNewswireFinancing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidates in Acumen's
8mo agoABOSAcumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS ForumGlobeNewswireNEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers
8mo agoABOSAcumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026GlobeNewswireNEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs)
11mo agoABOSAcumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewswireNEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs)
11mo agoABOSAcumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewswireNEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs)
11mo agoABOSAcumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's DiseaseGlobeNewswireNEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs)
12mo agoABOSAcumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewswireExpect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug
1y agoABOSAcumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of DirectorsGlobeNewswireNEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic
1y agoABOSAcumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025GlobeNewswireNEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic
1y agoABOSAcumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceGlobeNewswireNEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for
1y agoABOSAcumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
1y agoABOSAcumen Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireNEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for
1y agoABOSAcumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoABOSAcumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business HighlightsGlobeNewswireExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Expect decision to advance an oligomer-targeted Enhanced
1y agoABOSAcumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025GlobeNewswireNEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic
1y agoABOSAcumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025GlobeNewswireNEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs)
1y agoABOSAcumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer's DiseaseGlobeNewswireAcumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPreclinical candidate data
1y agoABOSAcumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025GlobeNewswireNEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs)
1y agoABOSAcumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewswireExpect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026 Cash, cash equivalents and marketable securities of
1y agoABOSAcumen Pharmaceuticals to Participate in the Bank of America Healthcare ConferenceGlobeNewswireNEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers
1y agoABOSAcumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025GlobeNewswireNEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic
1y agoABOSAcumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual MeetingGlobeNewswireNEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers
1y agoABOS CLYM LENZ SLDB+1Climb Bio Appoints Seasoned Biotech Leaders to Board of DirectorsGlobeNewswireWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors.
1y agoABOSAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business HighlightsGlobeNewswireEnrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease Anticipate topline results in late 2026 Topline results from the Phase 1 study
1y agoABOSAcumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's DiseaseGlobeNewswireNEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs)
1y agoABOSAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025GlobeNewswireNEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic
1y agoABOSAcumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy VolunteersGlobeNewswireWeekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration supports further clinical development Development of sabirnetug delivered
1y agoABOSAcumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer'sGlobeNewswireNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel O'Connell and Jessica Clark, DNP, RN, Dean of
1y agoABOSAcumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual MeetingGlobeNewswireNEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs)